This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Using Indices As Performance Benchmarks: An overview of why and how investors use indices as performance yardsticks to measure success.
16,658 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
May 2026 hands investors a surprise: a big jump in M2 money supply could rekindle inflation pressures. Markets weigh ...
Robinhood Chain goes live on mainnet, delivering Layer 2 scalability for tokenized assets and a suite of around-the-c...
Realty Income reports steady AFFO growth, near-full occupancy, and a secure monthly dividend, challenging the narrati...
As 2026 unfolds, I’m leaning into one magnificent ETF that fits my high-conviction approach. Here’s why this fund sta...
A historic clash over openness in software mirrors today’s AI debate, with investors watching who controls code, data...
Binance unveiled a sweeping move into the Philippines under a regulatory sandbox, a move critics say banks on Asia gr...
An investor explains a dip‑buying method focused on Nvidia, detailing how long‑term AI demand and enterprise commitme...
Rent prices are down nationwide, but smart investors aren’t scrambling — they’re adapting. This guide shares concrete...
XRP rebounded 8% this week, but the market remains range-bound. Traders eye key support and a critical breakout zone ...
Tech-led gains pushed the Nasdaq Composite higher as memory stocks rallied, signaling continued AI-driven demand and ...
ServiceNow posted a stronger-than-expected Q1 2026, lifting full-year guidance as Now Assist accelerates revenue. The...